These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18215089)

  • 1. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    BioDrugs; 2008; 22(1):37-44. PubMed ID: 18215089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
    So WY; Leung PS
    Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF21-based pharmacotherapy--potential utility for metabolic disorders.
    Gimeno RE; Moller DE
    Trends Endocrinol Metab; 2014 Jun; 25(6):303-11. PubMed ID: 24709036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
    Iglesias P; Selgas R; Romero S; Díez JJ
    Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity.
    Babaknejad N; Nayeri H; Hemmati R; Bahrami S; Esmaillzadeh A
    Horm Metab Res; 2018 Jun; 50(6):441-452. PubMed ID: 29883971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
    Dostálová I; Haluzíková D; Haluzík M
    Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.
    Sonoda J; Chen MZ; Baruch A
    Horm Mol Biol Clin Investig; 2017 May; 30(2):. PubMed ID: 28525362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFs and metabolism.
    Kharitonenkov A
    Curr Opin Pharmacol; 2009 Dec; 9(6):805-10. PubMed ID: 19683963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple roles of fibroblast growth factor 21 in metabolism.
    Li LI; Tang L
    Curr Pharm Des; 2015; 21(21):3041-50. PubMed ID: 25675147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases.
    Zhao L; Niu J; Lin H; Zhao J; Liu Y; Song Z; Xiang C; Wang X; Yang Y; Li X; Mohammadi M; Huang Z
    EBioMedicine; 2019 Oct; 48():462-477. PubMed ID: 31631034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.
    Izaguirre M; Gil MJ; Monreal I; Montecucco F; Frühbeck G; Catalán V
    Curr Diab Rep; 2017 Jun; 17(6):43. PubMed ID: 28451950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF21 as a therapeutic reagent.
    Zhao Y; Dunbar JD; Kharitonenkov A
    Adv Exp Med Biol; 2012; 728():214-28. PubMed ID: 22396172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies.
    Antonellis PJ; Kharitonenkov A; Adams AC
    J Anim Sci; 2014 Feb; 92(2):407-13. PubMed ID: 24398833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.
    Geng L; Lam KSL; Xu A
    Nat Rev Endocrinol; 2020 Nov; 16(11):654-667. PubMed ID: 32764725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factors: new insights, new targets in the management of diabetes.
    Kyrou I; Weickert MO; Gharanei S; Randeva HS; Tan BK
    Minerva Endocrinol; 2017 Sep; 42(3):248-270. PubMed ID: 27412358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic utilities of fibroblast growth factor 19.
    Wu X; Li Y
    Expert Opin Ther Targets; 2011 Nov; 15(11):1307-16. PubMed ID: 21961833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.
    Tan H; Yue T; Chen Z; Wu W; Xu S; Weng J
    Int J Biol Sci; 2023; 19(1):66-88. PubMed ID: 36594101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs.
    Kim KH; Lee MS
    J Endocrinol; 2015 Jul; 226(1):R1-16. PubMed ID: 26116622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic roles of endocrine fibroblast growth factors.
    Fernandes-Freitas I; Owen BM
    Curr Opin Pharmacol; 2015 Dec; 25():30-5. PubMed ID: 26531325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.